New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2013
14:45 EDTINCYIncyte presents final results from a Phase I trial of INCB024360
Incyte presented final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 IDO1, inhibitor, INCB024360, at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. IDO1 inhibition may provide a new approach in enhancing the immune system in patients with a variety of solid tumors. Data demonstrate that INCB024360 achieves greater than 90 percent inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies. Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
08:44 EDTINCYIncyte weakness creates buying opportunity, says Argus
Subscribe for More Information
September 12, 2014
13:48 EDTINCYArray names Sandor Chief Medical Officer to replace Needle
Subscribe for More Information
September 11, 2014
09:18 EDTINCYIncyte management to meet with Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use